Long Term Follow-Up
PreclinicalSmall molecule
Long Term Follow-Up is one of 9 small molecule programs targeting Menkes disease. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Menkes Disease
#DrugCompanyPhaseTrials
1Fludara
SanofiApproved
Jakafi
IncyteApproved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Busulfex
Akero TherapeuticsApproved
Dacogen
Sun PharmaApproved
Alkeran
AApotex Inc.
Approved
Northera
LundbeckPhase 2
Copper Histidine
CCyprium Therapeutics, Inc.
Phase 2
Long Term Follow-Up
SSentynl Therapeutics, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Long Term Follow-Up. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSentynl Therapeutics, Inc.